|
R&D Systems
recombinant human il 1ra Recombinant Human Il 1ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Recombinant+Human+IL-1ra%2FIL-1F3+Protein/10__1523_slash_jneurosci__20___23___j0004__2000-48-0-10 Average 94 stars, based on 1 article reviews
recombinant human il 1ra - by Bioz Stars,
2026-09
94/100 stars
|
Buy from Supplier |
|
R&D Systems
human il 1rα il 1f3 quantikine elisa kit Human Il 1rα Il 1f3 Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Human+IL-1ra%2FIL-1F3+Quantikine+ELISA+Kit/pmc07927573-175-9-14 Average 95 stars, based on 1 article reviews
human il 1rα il 1f3 quantikine elisa kit - by Bioz Stars,
2026-09
95/100 stars
|
Buy from Supplier |
|
R&D Systems
human il 1ra quantikine immunoassay Human Il 1ra Quantikine Immunoassay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Quantikine+Immunoassay+Control+Set+1000+for+Human+IL-1ra/pmc00506965-133-19-27 Average 90 stars, based on 1 article reviews
human il 1ra quantikine immunoassay - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
R&D Systems
il 1rn Il 1rn, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Human+IL-1ra%2FIL-1F3+Quantikine+ELISA+Kit/pm41352784-143-12-13 Average 94 stars, based on 1 article reviews
il 1rn - by Bioz Stars,
2026-09
94/100 stars
|
Buy from Supplier |
|
R&D Systems
il 1ra protein Il 1ra Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Recombinant+Human+IL-1ra%2FIL-1F3+Protein%2C+CF/pmc07041122-97-6-11 Average 94 stars, based on 1 article reviews
il 1ra protein - by Bioz Stars,
2026-09
94/100 stars
|
Buy from Supplier |
|
R&D Systems
human il 1ra il 1f3 duoset elisa Human Il 1ra Il 1f3 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Human+IL-1ra%2FIL-1F3+DuoSet+ELISA/pm41889175-194-25-30 Average 94 stars, based on 1 article reviews
human il 1ra il 1f3 duoset elisa - by Bioz Stars,
2026-09
94/100 stars
|
Buy from Supplier |
|
R&D Systems
human il 1ra duoset elisa kit Human Il 1ra Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Human+IL-1ra%2FIL-1F3+DuoSet+ELISA/pmc06433658-99-0-5 Average 94 stars, based on 1 article reviews
human il 1ra duoset elisa kit - by Bioz Stars,
2026-09
94/100 stars
|
Buy from Supplier |
|
Proteintech
anti il 1r1 Anti Il 1r1, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Human+IL-1R1+ELISA+Kit/pmc11920578-80-31-33 Average 94 stars, based on 1 article reviews
anti il 1r1 - by Bioz Stars,
2026-09
94/100 stars
|
Buy from Supplier |
|
MedChemExpress
il 1β ![]() Il 1β, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/IL-1RA%2FIL-1RN%2C+Human/pmc07307827-78-8-15 Average 93 stars, based on 1 article reviews
il 1β - by Bioz Stars,
2026-09
93/100 stars
|
Buy from Supplier |
|
R&D Systems
unconjugated first antibody ![]() Unconjugated First Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Human%2FMouse+IL-1ra%2FIL-1F3+Antibody/pmc00017821-201-6-11 Average 90 stars, based on 1 article reviews
unconjugated first antibody - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
R&D Systems
il1 ra ![]() Il1 Ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Recombinant+Human+IL-1ra%2FIL-1F3+Protein/pm39237258-50-7-19 Average 94 stars, based on 1 article reviews
il1 ra - by Bioz Stars,
2026-09
94/100 stars
|
Buy from Supplier |
|
R&D Systems
mouse anti human il 1ra antibodies ![]() Mouse Anti Human Il 1ra Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/human+il1ra/Human+IL-1ra%2FIL-1F3+Antibody/pm39121163-258-10-16 Average 92 stars, based on 1 article reviews
mouse anti human il 1ra antibodies - by Bioz Stars,
2026-09
92/100 stars
|
Buy from Supplier |
Image Search Results
Journal: International Journal of Molecular Medicine
Article Title: Hypercapnia exacerbates the disruption of the blood‑brain barrier by inducing interleukin‑1β overproduction in the blood of hypoxemic adult rats
doi: 10.3892/ijmm.2020.4604
Figure Lengend Snippet: Hypercapnia increased the expression of IL-1β in the hypoxic blood in vivo and in vitro (n=4). (A) There was an interaction effect between hypoxia treatment and hypercapnia treatment (P<0.01). (B) Simple effects analyses revealed increased IL-1β expression in the hypoxemia group ( ** P<0.01), but not in the hypercapnia group (P>0.05) compared with the Sham group. The expression levels of IL-1β were the highest in the HH group in comparison with the hypoxemia group ( ** P<0.01) and the hypercapnia group ( ** P<0.01). (C) There was an interaction effect between 0.2% O 2 treatment and 10% CO 2 treatment. (D) Simple effects analyses revealed increased IL-1β expression in the hypoxia group ( ** P<0.01), but not in the HC group (P>0.05) compared with the control group. The expression levels of IL-1β were the highest in the hypoxia + HC group compared with the hypoxia group ( ** P<0.01) and the HC group ( ** P<0.01). The concentrations of O 2 and CO 2 in the air were 21 and 0.03%, respectively. IL-1β, interleukin-1β; HH, hypercapnia + hypoxemia; ns, non‑significant; HC, high concentration of carbon dioxide.
Article Snippet: The IL-1β + IL-1Ra group was treated with
Techniques: Expressing, In Vivo, In Vitro, Comparison, Control, Concentration Assay
Journal: International Journal of Molecular Medicine
Article Title: Hypercapnia exacerbates the disruption of the blood‑brain barrier by inducing interleukin‑1β overproduction in the blood of hypoxemic adult rats
doi: 10.3892/ijmm.2020.4604
Figure Lengend Snippet: IL-1β treatment increased IL-1R1 and p-IRAK-1 expression in RBECs (n=4). (A) Immunoreactive bands of IL-1R1 (80 kDa) and β-actin (42 kDa). (B) The bar graph shows increased IL-1R1 expression in the IL-1β group compared with that in the control group ( ** P<0.01). (C) Immunofluorescence images showing the expression of CD31 + RBECs (a and d, green), IL-1R1 (b and e, red), and the co-localization of IL-1R1 and RBECs (c and f). Enhanced IL-1R1 immunofluorescence was evident in the IL‑1β group compared with the control group. Scale bars (a-f): 10 μ m. (D) Immunoreactive bands of p-RIAK-1 (77 kDa), t-IRAK-1 (77 kDa) and β-actin (42 kDa). (E) The bar graph shows increased p-IRAK-1 expression in the IL-1β group compared with the control group ( ** P<0.01). The protein expression of p‑IRAK‑1 was significantly suppressed with IL‑1Ra treatment ( * P<0.05). RBECs, rat brain capillary endothelial cells; IL-1β, interleukin-1β; IL‑1R, interleukin‑1 receptor; IL‑1Ra, interleukin‑1 receptor antagonist; HC, high concentration of carbon dioxide; ns, non‑significant.
Article Snippet: The IL-1β + IL-1Ra group was treated with
Techniques: Expressing, Control, Immunofluorescence, Concentration Assay
Journal: International Journal of Molecular Medicine
Article Title: Hypercapnia exacerbates the disruption of the blood‑brain barrier by inducing interleukin‑1β overproduction in the blood of hypoxemic adult rats
doi: 10.3892/ijmm.2020.4604
Figure Lengend Snippet: IL-1β treatment decreased the expression of tight junctional proteins in RBECs (n=4). (A) Immunoreactive bands of ZO-1 (220 kDa), occludin (59 kDa), claudin-5 (23 kDa) and β-actin (42 kDa). (B) There was decreased tight junctional protein expression in the IL-1β group compared with the control group (ZO-1: ** P<0.01; occludin: ** P<0.01; and claudin-5: ** P<0.01). The expression of tight junctional proteins was significantly upregulated following IL-1Ra treatment (ZO-1: ** P<0.01; occludin: ** P<0.01; and claudin-5: * P<0.05). RBECs, rat brain capillary endothelial cells; ZO-1, zonula occludens-1; IL-1β, interleukin-1β; IL‑1Ra, interleukin‑1 receptor antagonist; ns, non‑significant.
Article Snippet: The IL-1β + IL-1Ra group was treated with
Techniques: Expressing, Control
Journal: Molecular pain
Article Title: Rapid cleavage of IL-1β in DRG neurons produces tissue injury-induced pain hypersensitivity.
doi: 10.1177/17448069241285357
Figure Lengend Snippet: Figure 3. (a) The plantar incision induced a reduction in mechanical threshold against von Frey stimulation. Intrathecal IL-1RA administration significantly inhibited the reduction of the mechanical threshold for 6 h after the treatment. (b) The plantar incision induced a reduction in latency time against thermal stimulation. Intrathecal IL-1RA administration significantly inhibited reduction in the thermal pain latency for 6 h after the treatment. Data were analyzed by repeated measures two-way ANOVA, with Bonferroni’s multiple comparison test comparing pre- and post-treatment time points for each group (#p < .05, ##p < .01, ###p < .001), and Bonferroni’s multiple comparison test comparing both groups at each time point (*p < .05, **p < .01, ***p < .001). The data in the graphs are presented as the mean ± SEM (n = 6 in each group). i.t.: intrathecal administration. Intrathecal administration of IL-1β induced reduction of the mechanical threshold against von Frey stimulation (c) and reduction of latency time against thermal stimulation (d). Data were analyzed by repeated measures two-way ANOVA, with Bonferroni’s multiple comparison test comparing pre- and post-treatment time points for each group (#p < .05, ##p < .01) and Bonferroni’s multiple comparison test comparing both groups at each time point (*p < .05, **p < .01). The data in the graphs are presented as the mean ± SEM (n = 6 in each group).
Article Snippet: Mice were randomly assigned to saline and
Techniques: Comparison
Journal: Proceedings of the National Academy of Sciences of the United States of America
Article Title: IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.
doi: 10.1073/pnas.2405644121
Figure Lengend Snippet: Fig. 1. Effect of anakinra on NFκB in CLL cells in vitro. (A) RNAseq was performed on CLL cells from 3 patients cultured with or without anakinra for 24 h. The enrichment plot indicates downregulation of NFκB-activated genes by anakinra. (B–D) CLL cells from untreated patients were cultured for 24 h with or without resiquimod (S) at 1 μg/ml (B) or resiquimod and IL-2 (2S) at 500 IU/ml (C and D) in the presence and absence of anakinra (K). (B) Phospho-p65 was quantified in lysates collected at the indicated times by immunoblotting and densitometry using β-actin as a loading control. A sample blot is shown above the summary graph, indicating averages and SE for 7 patient samples. The averages and SEM at each time point (S vs S + K) are 0.848±0.111 vs 1.308 ± 0.220; 1.167 ± 0.161 vs 1.177 ± 0.263; 1.586 ± 0.103 vs 1.263 ± 0.125; 1.174 ± 0.174 vs 0.822 ± 0.133; 1.235 ± 0.159 vs 0.702 ± 0.163; 1.087 ± 0.075 vs 0.484 ± 0.105. (C) The lines (N = 10) indicate TNFα in culture supernatants measured by the ELISA for single patient samples. (D) Cell surface CD83 was measured by flow cytometry (N = 6). Examples of histograms are shown, with the numbers representing differences between percentages of cells stained with CD83 antibody (red histogram) or control antibodies (gray histogram). (E and F) p105/50 and p100/52 were measured in CLL cells cultured alone (E) or with TNFα (10 ng/ml) or trimeric CD40L (1 μg/ml) to activate canonical and noncanonical NFκB, respectively (F) with or without anakinra. Examples are shown. Averages and SE for (E) are p105: 0.948 ± 0.146 vs 0.821 ± 0.119, p50: 1.187 ± 0.125 vs 0.947 ± 0.105 (N = 19), p100: 0.6 ± 0.121 vs 0.355 ± 0.132, and p52: 0.404 ± 0.121 vs 0.48 ± 0.096 (N = 16) and for (F) are p105: 1.090 ± 0.203 vs 0.824 ± 0.198, p50: 1.125 ± 0.186 vs 0.713 ± 0.138 (N = 6), p100: 0.934 ± 0.182 vs 0.980 ± 0.121, and p52: 1.458 ± 0.176 vs 1.158 ± 0.186 (N = 8). Each closed circle in the summary graphs indicates results for a single sample. Statistical significance was determined with Student’s t tests and one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Article Snippet: They were then stained overnight at 4 °C with primary
Techniques: In Vitro, Cell Culture, Western Blot, Control, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Staining
Journal: Proceedings of the National Academy of Sciences of the United States of America
Article Title: IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.
doi: 10.1073/pnas.2405644121
Figure Lengend Snippet: Fig. 2. Localization of anakinra and effect on oxidative stress in CLL cells. (A) IL-1α (1.24 ± 1.006) (N = 3 0), IL-1β (0.997 ± 0.158) (N = 34), and IL-1Ra (98.475±28.467) (N = 28) were measured in supernatants of CLL cells after 48 h. Patient numbers differ because samples were assayed in different batch- es. Each circle is the result for an individ- ual sample. Averages and SE are shown. (B) CLL cells were stimulated with IL-1β or resiquimod (S) (N = 3). Phospho-p38 was quantified after 30 min by immunoblotting and densitometry with β-actin as a loading control. A representative blot is shown. In- dividual patient samples in the graph are indicated by dots. Averages and SE are Con: 0.33 ± 0.201, IL-1β: 0.264 ± 0.003, and S: 3.497 ± 0.458. (C) CLL cells precultured with or without neutralizing IL-1 receptor antibodies for 2 h before adding IL-2 and resiquimod (2S) in the presence or absence of anakinra (K) for 48 h were analyzed by confocal microscopy as described in the materials and methods. Representative images are shown, with similar results ob- tained with 5 different patient samples. (D) IL-1Ra-staining quantified for 5 images per treatment per patient sample is shown in the summary graph, with each dot repre- senting a different image. Averages and SE of mean fluorescence intensities (MFIs) are Con: 91.407 ± 3.589, 2S:169.692 ± 38.945, 2S+K:1263.622 ± 145.864, and 2S+K + anti- IL-1RI: 1741.328 ± 208.275. (E) CLL cells (N = 7) were cultured with or without anak- inra (K) for 48 h and stained with DCFH to measure intracellular ROS levels. Rep- resentative histograms (Left) and MFIs of DCFH staining for individual patient samples (Right) are shown. Statistical significance was determined using Student’s t tests. *P < 0.05; **P < 0.01; ns, not significant.
Article Snippet: They were then stained overnight at 4 °C with primary
Techniques: Western Blot, Control, Confocal Microscopy, Staining, Fluorescence, Cell Culture
Journal: Proceedings of the National Academy of Sciences of the United States of America
Article Title: IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.
doi: 10.1073/pnas.2405644121
Figure Lengend Snippet: Fig. 4. Effect of anakinra on IFN responses in CLL cells in vivo and in vitro. (A) DEGs in circulating CLL cells from six patients at C1D1 and C1D14 were compared by GSEA. The enrichment plot indicates that anakinra up-regulated IFN-stimulated gene expression. (B) Phospho-STAT2 was measured in protein extracts from cryopreserved CLL cells obtained at C1D1 and C1D14 (N = 5) by immunoblotting and densitometry using β-actin as a loading control. (C and D) CLL cells were cultured with and without anakinra (K). Phospho-STAT2 (exposure time 1 min) was measured after 24 h (N = 11) (C). CXCL10 was measured by the ELISA after 48 h (N = 10) (D). (E–G) CLL cells were cultured with or without anakinra for 24 h and then stimulated with IFNβ. E. OASL transcripts were measured after 4 h (N = 11). Averages and SE are Con: 0.219 ± 0.076, K: 0.386 ± 0.117, IFNβ: 7.41 ± 1.617, K + IFNβ: 10.115 ± 2.041. (F) Phospho-STAT1 and -STAT2 (exposure time 5 s) were measured after 30 min (N = 7). Averages and SE are Con: 0.09 ± 0.032, IFNβ: 1.271 ± 0.197, K: 0.098 ± 0.035, K + IFNβ: 2.348 ± 0.244 for P-STAT1 and Con: 0.063 ± 0.024, IFNβ: 1.161 ± 0.254, K: 0.058 ± 0.018, K + IFNβ: 2.395 ± 0.456 for P-STAT2. (G) LAG3 was measured after 24 h. A representative example is shown in Supplementary Fig. S6. Percentages of LAG3+ cells in each condition normalized to the result for IFN-treated cells without anakinra are plotted in the summary graph. Examples of immunoblots are shown, and each line or dot in the graphs represents results for an individual patient. The means and SEMs normalized to IFNβ are Con: 0.251 ± 0.045, K: 0.327 ± 0.117, IFNβ: 1 ± 0, and IFNβ+K: 1.183 ± 0.045. (H and I) CLL cells were cultured in RPMI-1640 in the absence (H) or presence (I) of IFNβ with or without K, anifrolumab (ANI), or both (N = 14). Live (DAPI−) cells were measured after 4 d. Examples of contour plots are shown, with numbers indicating % DAPI− cells. Each dot in the summary graphs represents an individual patient. (H) Averages and SE of % live cells are Con: 29.666 ± 1.591, K: 38.369 ± 2.546, ANI: 30.65 ± 1.733, and K + ANI: 31.428 ± 2.104. (I) Averages and SE are Con: 60.839 ± 5.642, K + IFNβ: 78.786 ± 4.617, K + IFNβ+ANI: 51.804 ± 6.57. Statistical analysis was performed with Student’s t tests and one-way ANOVAs. *P < 0.05; **P < 0.01; ****P < 0.0001; ns, not significant.
Article Snippet: They were then stained overnight at 4 °C with primary
Techniques: In Vivo, In Vitro, Gene Expression, Western Blot, Control, Cell Culture, Enzyme-linked Immunosorbent Assay